Evidence map›Paper›PMID 41603564›Full record

ArticleJournal of medicinal chemistry2026

Systematic Optimization of Fragment TLX Ligands toward Agonism and Inverse Agonism.

Emily C Hank, Loris Knümann, Úrsula López-García, Arthur Kardanov, Vasily Morozov, Georg Höfner, Daniel Merk

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emily C HankDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich 81377, Germany.ORCID 0000-0002-3777-4697
Loris KnümannDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
Úrsula López-GarcíaDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich 81377, Germany.ORCID 0000-0003-2557-9584
Arthur KardanovDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
Vasily MorozovDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
Georg HöfnerDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
Daniel MerkDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich 81377, Germany.ORCID 0000-0002-5359-8128

Funding

European Research Council 101040355
6 · The paper itself

Abstract

The transcription factor tailless homologue (TLX, NR2E1) maintains persistence of neural stem cells (NSCs) in a proliferating, undifferentiated state, thereby controlling NSC homeostasis and enabling neurogenesis. TLX is responsive to small-molecule ligands, offering potential access to new neuroprotective treatments, but TLX ligands are very rare. Here, we used a drug fragment screening hit as lead to develop TLX modulators and identified substructures tuning activity between agonism and inverse agonism. Structural optimization provided potent TLX activating and inhibiting fragment ligands with validated binding and favorable ligand efficiency for structural extension.

Indexed as

Drug Inverse AgonismReceptors, Cytoplasmic and NuclearAnimalsHumansLigandsNeural Stem CellsOrphan Nuclear ReceptorsStructure-Activity RelationshipLigandsNR2E1 protein, humanOrphan Nuclear ReceptorsReceptors, Cytoplasmic and Nuclear

Identifiers

PMID41603564
PMCPMC7618817

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.